ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0438

Characterization of Interstitial Lung Disease in the Presence of Antineutrophil Cytoplasmic Antibodies

Khai-Tuan Andrew Bui1, Rachel Richard2, Ariane Drouin3, Nader Toban1, Marianne Levesque4, Rosalie-Selene Meunier5, Carolyn Ross6 and Jean-Paul Makhzoum3, 1Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montréal, QC, Canada, 2Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Laval, QC, Canada, 3Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montréal, QC, Canada, 4Division of Respirology, Department of Medicine, Hopital du Sacre-Coeur de Montreal, University of Montreal, Montréal, QC, Canada, 5Hopital Sacre-Coeur, Universite de Montreal, Montréal, QC, Canada, 6University of Montreal, Montréal, QC, Canada

Meeting: ACR Convergence 2022

Keywords: ANCA, ANCA associated vasculitis, interstitial lung disease, pulmonary, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Vasculitis – ANCA-Associated Poster I: Epidemiology, Outcomes, and Classification

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Various pulmonary manifestations may occur in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). ANCA-related interstitial lung disease (ILD) has recently been described in patients with or without overt AAV. The significance and evolution of this association remains unclear and has been raising research efforts in the past years. This study aims to compare 1) characteristics, 2) clinical course and 3) treatments of patients with ILD and positive ANCA, to those without positive ANCA.

Methods: A retrospective chart review was performed in all patients who had a follow-up from 2018 to 2021 at the ILD clinic or vasculitis clinic in our academic center. Patients with available ANCA results and at least two clinic visits were included. For each visit, data was collected regarding patient characteristics, clinical presentation, bloodwork, imaging, pulmonary function tests, hospitalizations, and treatments. Radiological patterns described on high resolution computed tomography (HRCT) stemmed from official reports generated by pulmonary radiologists and were validated by respirologists in charge of the ILD clinic. Descriptive statistics are reported to compare characteristics of patients with ANCA-related ILD, to those with ILD without positive ANCA.

Results: 265 patients with ILD were included with a mean follow-up duration of 69.3 (± 10.6) months. Amongst these patients, 26 (9.8%) showed ANCA positivity (proteinase 3 and/or myeloperoxidase). Baseline characteristics are presented in table 1. The most frequent final clinical diagnosis in the ANCA-negative group was idiopathic pulmonary fibrosis, whereas connective tissue disease-associated ILD was more prevalent in the ANCA-positive group. The most common patterns on HRCT found in those with positive ANCA were usual interstitial pneumonia, nonspecific interstitial pneumonia and organizing pneumonia (table 2). A total of 17 (65.4%) patients with positive ANCA had a clinical diagnosis of AAV at some point during the follow-up period. In 5 (29.4%) patients, AAV developed following ILD diagnosis. No significant differences in pulmonary disease evolution over time was found between patients with ANCA-positive ILD and ANCA-negative ILD (figure 1). However, patients with ILD and positive ANCA received significantly more glucocorticoids, immunosuppressive therapy and had more hospitalizations of all cause (table 2).

Conclusion: This study involved a large cohort of patients with ILD. Due to the ANCA positivity rate and risk of developing AAV over time, ANCA testing should be considered in patients with ILD. Further prospective research is required to improve management of patients with ANCA-related ILD.

Supporting image 1

Table 1: Baseline characteristics of patients with ILD

Supporting image 2

Table 2: Comparison of baseline ancillary tests and outcomes on the basis of ANCA results

Supporting image 3

Figure 1: Evolution between the first and last clinic visits with regards to ANCA results


Disclosures: K. Bui, None; R. Richard, None; A. Drouin, None; N. Toban, None; M. Levesque, None; R. Meunier, None; C. Ross, None; J. Makhzoum, None.

To cite this abstract in AMA style:

Bui K, Richard R, Drouin A, Toban N, Levesque M, Meunier R, Ross C, Makhzoum J. Characterization of Interstitial Lung Disease in the Presence of Antineutrophil Cytoplasmic Antibodies [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/characterization-of-interstitial-lung-disease-in-the-presence-of-antineutrophil-cytoplasmic-antibodies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-interstitial-lung-disease-in-the-presence-of-antineutrophil-cytoplasmic-antibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology